PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non–Small Cell Lung Cancer
Marcelo V. Negrao, Vincent K. Lam, Alexandre Reuben, Maria Laura Rubin, Lara Lacerda Landry, Emily B. Roarty, Waree Rinsurongkawong, Jeff Lewis, Jack A. Roth, Stephen G. Swisher, Don L. Gibbons, Ignacio I. Wistuba, Vassiliki Papadimitrakopoulou, Bonnie S. Glisson, George R. Blumenschein, J. Jack Lee, John V. Heymach, Jianjun Zhang
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non–Small Cell Lung Cancer'. Together they form a unique fingerprint.